|
|
||||||||


Abstract. Halofantrine (WR 171,669) was administered to 27 nonimmune subjects infected with the multi-drug resistant Vietnam Smith strain of Plasmodium falciparum. It was also administered to three other subjects, one infected with the Cambodian Buchanan strain of P. falciparum, and two with blood-induced infection with the Chesson strain of P. vivax. It cured infections with all three parasites. Against the highly chloroquine-resistant Smith strain, it was curative in single day treatment regimens. The drug was well tolerated and produced rapid clearance of parasitemia in every case.
Accepted for publication May 6, 1982.
The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.
* The subjects in these studies were United States Army personnel at the United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, as well as civilians from the Washington, DC area. The studies were governed by the principles, policies, and rules for medical volunteers as established by Army Regulation 70-25 and the Declaration of Helsinki.
Present address: World Health Organization, The Malaria Division, Ministry of Public Health, Devavesm Palace, Bangkok 2, Thailand.
Present address: Head, Anti-Infectives Section, Medical Department, Burroughs Wellcome Co., 3030 Cornwallis Road, Research Triangle Park, North Carolina 27709.
This article has been cited by other articles:
![]() |
A. M Croft A lesson learnt: the rise and fall of Lariam and Halfan J R Soc Med, April 1, 2007; 100(4): 170 - 174. [Full Text] [PDF] |
||||
![]() |
M. Mbai, S. Rajamani, and C. T January The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels Cardiovasc Res, September 1, 2002; 55(4): 799 - 805. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |